Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clinical Genomics, |
RCV002267091 | SCV002522309 | uncertain significance | Transitory neonatal diabetes mellitus | criteria provided, single submitter | research | Mutations in ABCC8 gene are associated with both neonatal diabetes mellitus as well as MODY. Patients with this mutation may have a better response to sulfonylureas. However, no sufficient evidence is found to ascertain the role of this particular variant ( rs374869130) in neonatal diabetes yet. | |
Clinical Genomics, |
RCV002267090 | SCV002522310 | uncertain significance | Maturity onset diabetes mellitus in young | criteria provided, single submitter | research | Mutations in ABCC8 gene are associated with both neonatal diabetes mellitus as well as MODY. Patients with this mutation may have a better response to sulfonylureas. However, no sufficient evidence is found to ascertain the role of this particular variant ( rs374869130) in MODY yet. | |
Fulgent Genetics, |
RCV002493477 | SCV002793708 | uncertain significance | Diabetes mellitus, transient neonatal, 2; Hyperinsulinemic hypoglycemia, familial, 1; Leucine-induced hypoglycemia; Type 2 diabetes mellitus; Diabetes mellitus, permanent neonatal 3 | 2021-07-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002541682 | SCV003546435 | uncertain significance | Inborn genetic diseases | 2022-11-15 | criteria provided, single submitter | clinical testing | The c.1923+3G>A intronic alteration consists of a G to A substitution 3 nucleotides after coding exon 13 of the ABCC8 gene. Based on data from the Genome Aggregation Database (gnomAD) database, the ABCC8 c.1923+3G>A alteration was observed in 0.01% (24/282294) of total alleles studied, with a frequency of 0.09% (23/24958) in the African subpopulation. This nucleotide position is not conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004699258 | SCV005204781 | uncertain significance | not specified | 2024-06-17 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001278415 | SCV001465428 | uncertain significance | Hereditary hyperinsulinism | 2020-04-10 | no assertion criteria provided | clinical testing |